ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1480

Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients

Samina A. Turk1, Dirkjan van Schaardenburg1,2, Willem F. Lems1,3 and Mike T. Nurmohamed1,3, 1Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, 2Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 3Rheumatology, Amsterdam Rheumatology and immunology Center, VU University medical center, Amsterdam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cardiovascular disease, Comorbidity, Lipids, rheumatoid arthritis (RA) and risk

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular morbidity and mortality. This cardiovascular risk is mainly determined by the lipid profile, which may change during the course of the disease(1). For a proper cardiovascular risk assessment stable lipid values should be used and in cardiovascular risk prediction models mostly lipid ratios are applied. As the increased cardiovascular risk is already present at the time of diagnosis, it is important to initiate cardiovascular risk management as early as possible in the disease(2). However, first it is necessary to know if measurement of the lipid profile is adequate (i.e. stable lipid values) early in the disease. The aim of this study was to 1) investigate the change in lipid profile during the first 4 weeks of RA treatment 2) analyse the association between the alteration in the lipid profile and the change in ESR.

Methods: In 66 consecutive DMARD-naive early RA patients lipid profile and disease activity were measured. This was repeated after four weeks of treatment with methotrexate (3 weeks 10 mg, 4th week 17.5 mg) and prednisolone (30 mg tapered to 10 mg). Lipid profile assessment comprised TC, HDL-C, LDL-C, triglycerides and apolipoprotein A and B (Apo A and Apo B). Disease activity was assessed by the disease activity score of 44 joints (DAS44), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Patients on statins were excluded. The change in lipid profile (week 4 minus week 0) versus change in ESR was analysed in 2 patient groups: a group with high (median -31.0 mm/h) and a group with low (median -3.0 mm/h) improvement in ESR.

Results: Three patients on statins were excluded, analyses were thus performed on 63 early RA patients. All components of the lipid profile increased significantly during treatment, except for Apo B. In addition, ratios of lipid values, particularly the TC/HDL cholesterol ratio improved significantly (table 1). The group with high ESR versus the group with low ESR improvement had a significantly higher increase in TC, HDL-C, LDL-C and Apo A levels. This was 2.7% in the group with less improvement in ESR and 23.1% in the most improvement group. The spearman rho test showed a correlation between delta ESR and delta TC, HDL, LDL and Apo A of r=0.456, r=0.313, r=0.507 and r=0.281, respectively (all p<0.05).

Conclusion: Lipid levels increased significantly after four weeks of methotrexate and prednisolone treatment after RA diagnosis and this change is associated with the improvement in ESR. In both groups ratios of lipid values improved substantially. Hence, cardiovascular risk management in early arthritis should be postponed until low disease activity has been obtained, as assessment during active disease leads to an inappropriately high cardiovascular risk estimation. References: 1) Nat Rev Rheumatol 2013 Sep;9(9):513-23. 2) Arthritis Res Ther 2010;12(4):R158.


Disclosure: S. A. Turk, None; D. van Schaardenburg, None; W. F. Lems, None; M. T. Nurmohamed, None.

To cite this abstract in AMA style:

Turk SA, van Schaardenburg D, Lems WF, Nurmohamed MT. Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/determination-of-the-lipid-profile-in-active-disease-leads-to-incorrect-cardiovascular-risk-prediction-in-early-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/determination-of-the-lipid-profile-in-active-disease-leads-to-incorrect-cardiovascular-risk-prediction-in-early-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology